Literature DB >> 3582473

Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam.

C J Richardson, K L Blocka, S G Ross, R K Verbeeck.   

Abstract

Piroxicam (20 mg once daily) was administered orally to six healthy young volunteers for 15 days. Trough steady-state levels of piroxicam and 5'-hydroxypiroxicam were 5.5 and 1.2 micrograms/ml, respectively. Piroxicam's plasma half-life (54.9 h) was significantly shorter than that of 5'-hydroxypiroxicam (70.5 h). Percent unbound piroxicam and 5'-hydroxypiroxicam in plasma at steady-state averaged 1.10 and 8.07 respectively. An average of 25.2% of the dose was recovered in urine as 5'-hydroxypiroxicam; approximately two-thirds (17.2%) in the form of the glucuronide conjugate. Average steady-state plasma levels (Css) of piroxicam (7.0 micrograms/ml) were significantly higher than predicted from a previously reported single dose study (5.3 micrograms/ml).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3582473     DOI: 10.1007/bf00609964

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  High-performance liquid chromatographic analysis of piroxicam and its major metabolite 5'-hydroxypiroxicam in human plasma and urine.

Authors:  C J Richardson; S G Ross; K L Blocka; R K Verbeeck
Journal:  J Chromatogr       Date:  1986-10-31

2.  Clinical pharmacokinetics of piroxicam.

Authors:  R K Verbeeck; C J Richardson; K L Blocka
Journal:  J Rheumatol       Date:  1986-08       Impact factor: 4.666

3.  Single-dose and steady-state pharmacokinetics of piroxicam in elderly vs young adults.

Authors:  A Darragh; A J Gordon; H O'Byrne; D Hobbs; E Casey
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Comparative steady state pharmacokinetic study of piroxicam and flurbiprofen in normal subjects.

Authors:  H J Rogers; R G Spector; P J Morrison; I D Bradbrook
Journal:  Eur J Rheumatol Inflamm       Date:  1981

5.  Synthesis and antiinflammatory activity of metabolites of piroxicam.

Authors:  J G Lombardino
Journal:  J Med Chem       Date:  1981-01       Impact factor: 7.446

Review 6.  Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

7.  Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies.

Authors:  D C Hobbs; T M Twomey
Journal:  J Clin Pharmacol       Date:  1979 May-Jun       Impact factor: 3.126

Review 8.  Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.

Authors:  R K Verbeeck; J L Blackburn; G R Loewen
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

9.  Effects of age and sex on piroxicam disposition.

Authors:  C J Richardson; K L Blocka; S G Ross; R K Verbeeck
Journal:  Clin Pharmacol Ther       Date:  1985-01       Impact factor: 6.875

  9 in total
  10 in total

Review 1.  Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.

Authors:  C Litalien; E Jacqz-Aigrain
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

2.  Plasma tenoxicam concentrations after single and multiple oral doses.

Authors:  C Crevoisier; P Heizmann; I Forgo; U C Dubach
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jan-Mar       Impact factor: 2.441

3.  Oral bioavailability of CHF1194, an inclusion complex of piroxicam and beta-cyclodextrin, in healthy subjects under single dose and steady-state conditions.

Authors:  X Deroubaix; A Stockis; A M Allemon; E Lebacq; D Acerbi; P Ventura
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Analysis of piroxicam in pharmaceutical formulation and human urine by dispersive liquid-liquid microextraction combined with spectrophotometry.

Authors:  Ahad Bavili Tabrizi; Nakisa Seyyedeh Tutunchi
Journal:  Adv Pharm Bull       Date:  2013-02-07

5.  Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism.

Authors:  Chang-Keun Cho; Pureum Kang; Hye-Jung Park; Eunvin Ko; Chou Yen Mu; Yun Jeong Lee; Chang-Ik Choi; Hyung Sik Kim; Choon-Gon Jang; Jung-Woo Bae; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2022-05-31       Impact factor: 4.946

6.  Steady state pharmacokinetics of piroxicam in children with rheumatic diseases.

Authors:  A L Mäkelä; K T Olkkola; M J Mattila
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis.

Authors:  T S Tracy; T Worster; J D Bradley; P K Greene; D C Brater
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

Review 8.  Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms.

Authors:  Michael H Court
Journal:  Vet Clin North Am Small Anim Pract       Date:  2013-09       Impact factor: 2.093

9.  The pharmacokinetics of piroxicam in elderly persons with and without renal impairment.

Authors:  A C Rudy; N L Figueroa; S D Hall; D C Brater
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of tenoxicam.

Authors:  O G Nilsen
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.